Unveiling 15 Analyst Insights On Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed evaluations of Sarepta Therapeutics (NASDAQ:SRPT) over the past three months, with a majority being somewhat bullish. The average 12-month price target is $176.93, a decrease from the previous $185.17. Sarepta has shown strong revenue growth and net margin but faces challenges with ROE. Analysts' ratings and price targets reflect their varied perspectives on the company's market standing.
October 21, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sarepta Therapeutics has received mixed analyst ratings, with a majority being somewhat bullish. The average 12-month price target is $176.93, down from $185.17. The company has shown strong revenue growth and net margin but faces challenges with ROE.
The mixed analyst ratings indicate a neutral short-term impact on SRPT's stock price. While the company shows strong revenue growth and net margin, the decrease in average price target and challenges with ROE suggest a balanced outlook. The majority of analysts are somewhat bullish, but the overall sentiment is mixed, leading to a neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100